Streetbeat News

Price Targets

TVTX

Stifel analyst Alex Thompson has maintained a Hold rating on Travere Therapeutics (NASDAQ:TVTX) and increased the price target from $8 to $10.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 3:54 pm

TH

Stifel analyst Stephen Gengaro has maintained a Buy rating on Target Hospitality (NASDAQ:TH) but has reduced the price target from $19 to $14.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 3:52 pm

PGR

Wells Fargo analyst Elyse Greenspan has upgraded Progressive (NYSE: PGR) from Equal-Weight to Overweight and increased the price target from $144 to $176.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 3:52 pm

TH

Stifel analyst Stephen Gengaro has maintained a Buy rating on Target Hospitality (NASDAQ:TH) but reduced the price target from $19 to $14.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 3:52 pm

SYRE

Stifel analyst Alex Thompson has reaffirmed a Buy rating on Spyre Therapeutics (NASDAQ:SYRE) and increased the price target from $23 to $27.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 3:50 pm

NFLX

Morgan Stanley analyst Benjamin Swinburne has maintained an Overweight rating on Netflix (NASDAQ:NFLX) and increased the price target from $475 to $550.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 3:49 pm

REGN

Truist Securities analyst Robyn Karnauskas has reiterated a Buy rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and maintained a price target of $1045.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 3:45 pm

M

Jefferies reports that Macy's has received additional buyout interest from private equity firm Sycamore Partners. Jefferies maintains a fair value range for Macy's stock at $25-$32 and reiterates a 1-year price target of $27.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 3:43 pm

PBLA

Roth MKM analyst Jonathan Aschoff has reiterated a Buy rating on Panbela Therapeutics (NASDAQ:PBLA) and maintained a $25 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 3:41 pm

VSEC

VSE Corporation (NASDAQ:VSEC) has received positive analyst ratings in the last quarter, with 4 bullish and 2 somewhat bullish ratings. The average 12-month price target for VSE is $75.33, with a high of $85.00 and a low of $65.00, reflecting an 11.88% increase from the previous average of $67.33. Analysts from Benchmark and Truist Securities have raised their price targets, while RBC Capital has both raised and maintained targets. VSE's financial performance shows strong revenue growth, net margin, and ROA, but a lower ROE and a sound debt-to-equity ratio. The company operates in aftermarket products and services for transportation assets.

Portfolio Pulse from Benzinga Insights

December 18, 2023 | 3:39 pm